Brind.

Veru anticipates FDA feedback on its regulatory pathway after the QUALITY study showed positive efficacy and safety data.

2 reports, 1 independent Updated Aug 12
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Veru anticipates FDA feedback on its regulatory pathway after the QUALITY study showed positive efficacy and safety data.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireVeru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to sema
  • GlobeNewswireVeru to Participate in the 2025 BTIG Virtual Biotech Conference MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on devel